Generated by AI
Senseonics Holdings, Inc. is a commercial-stage medical technology company specializing in long-term, implantable continuous glucose monitoring systems for people with diabetes in the United States and internationally. The company’s Eversense product family, including Eversense, Eversense XL, Eversense E3, and Eversense 365, uses a small sensor inserted under the skin, a removable and rechargeable smart transmitter worn on the body, and a mobile application that delivers real-time glucose readings and alerts. These systems are designed to provide extended wear duration compared with traditional transcutaneous CGM devices, supporting continuous monitoring without frequent sensor replacement. Senseonics focuses on the development and manufacturing of these glucose monitoring products and distributes them through healthcare providers, distributors, and strategic commercial partners, serving the global diabetes community. Headquartered in Germantown, Maryland, Senseonics plays a specialized role in the medical technology and diabetes care market by offering differentiated implantable CGM solutions intended to support more informed and convenient day-to-day glucose management.
Website20451 Seneca Meadows Parkway
Germantown, MD, 20876-7005
United States
The latest articles about SENS.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Summary of Feb 11's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about SENS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.